Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma

Oncogene volume 24, pages 5218–5225 (2005)Cite this article

Abstract

Fibroblast growth factor receptor 3 (FGFR3) mutations are frequent in superficial urothelial cell carcinoma (UCC). Ras gene mutations are also found in UCC. As oncogenic activation of both FGFR3 and Ras is predicted to result in stimulation of the mitogen-activated protein kinase (MAPK) pathway, we hypothesized that these might be mutually exclusive events. HRAS mutation has been widely studied in UCC, but all three Ras gene family members have not been screened for mutation in the same sample series. We screened 98 bladder tumours and 31 bladder cell lines for mutations in FGFR3, HRAS, NRAS and KRAS2. FGFR3 mutations were present in 54 tumours (55%) and three cell lines (10%), and Ras gene mutations in 13 tumours (13%) and four cell lines (13%). These included mutations in all three Ras genes; ten in HRAS, four in KRAS2 and four in NRAS and these were not associated with either tumour grade or stage. In no cases were Ras and FGFR3 mutation found together. This mutual exclusion suggests that FGFR3 and Ras gene mutation may represent alternative means to confer the same phenotype on UCC cells. If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E and Gultekin EY . (2001). Int. Urol. Nephrol., 33, 363–367.

  • Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK and de Medina SG . (2003). Cancer Res., 63, 8108–8112.

  • Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ and Francomano CA . (2000). Am. J. Hum. Genet., 67, 1411–1421.

  • Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP and Radvanyi F . (2001). Am. J. Pathol., 158, 1955–1959.

  • Burchill SA, Neal DE and Lunec J . (1994). Br. J. Urol., 73, 516–521.

  • Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and Radvanyi F . (1999). Nat. Genet., 23, 18–20.

  • Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM and Bergsagel PL . (2001). Blood, 97, 729–736.

  • Czerniak B, Deitch D, Simmons H, Etkind P, Herz F and Koss LG . (1990). Br. J. Cancer, 62, 762–763.

  • Der CJ, Krontiris TG and Cooper GM . (1982). Proc. Natl. Acad. Sci. USA, 79, 3637–3640.

  • Elliot AY, Cleveland P, Cervenka J, Castro AE, Stein N, Hakala TR and Fraley EE . (1974). J. Natl. Cancer Inst., 53, 1341–1349.

  • Ellis CA and Clark G . (2000). Cell. Signal., 12, 425–434.

  • Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA and Summerhayes IC . (1995). J. Natl. Cancer Inst., 87, 129–133.

  • Fogh J . (1978). Natl. Cancer Inst. Monogr., 49, 5–9.

  • Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M and Aaronson SA . (1984). Nature, 309, 464–466.

  • Grimmond SM, Raghavan D and Russell PJ . (1992). Urol. Res., 20, 121–126.

  • Grossman HB, Wedemeyer G, Rem L, Wilson GL and Cox B . (1986). J. Urol., 136, 953–959.

  • Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA and Donoghue DJ . (2000). Oncogene, 19, 3309–3320.

  • Huang MY and Cohen JB . (1997). Oncol. Res., 9, 611–621.

  • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ . (2003). CA Cancer J. Clin., 53, 5–26.

  • Knowles MA . (1999). BJU Int., 84, 412–427.

  • Knowles MA and Williamson M . (1993). Cancer Res., 53, 133–139.

  • Kyriazis AA, Kyriazis AP, McCombs III WB and Peterson WBJ . (1984). Cancer Res., 44, 3997–4005.

  • Levesque P, Ramchuuren N, Saini K, Joyce A, Libertino J and Summerhayes IC . (1993). Int. J. Cancer, 55, 785–790.

  • Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR and Franks LM . (1986). Cancer Res., 46, 3630–3636.

  • Nayak SK, O'Toole C and Price ZH . (1977). Br. J. Cancer, 35, 142–151.

  • O'Toole C, Nayak S, Price Z, Gilbert WH and Waisman J . (1976). Int. J. Cancer, 17, 707–714.

  • O'Toole C, Price ZH, Ohnuki Y and Unsgaard B . (1978). Br. J. Cancer, 38, 64–76.

  • Olderoy G, Daehlin L and Ogreid D . (1998). Anticancer Res., 18, 2675–2678.

  • Ooi A, Herz F, Ii S, Cordon-Cardo C, Fradet Y, Mayall BH and Cancer NMNfB. (1994). Int. J. Oncol., 4, 85–90.

  • Oxford G and Theodorescu D . (2003). J. Urol., 170, 1987–1993.

  • Paulie S, Hansson Y, Lundblad ML and Perimann P . (1983). Int. J. Cancer, 31, 297–303.

  • Pratsinis H, Saetta A, Gagos S and Davaris P . (1998). In vitro Cell. Dev. Biol. Anim., 34, 722–728.

  • Proctor AJ, Coombs LM, Cairns JP and Knowles MA . (1991). Oncogene, 6, 789–795.

  • Przybojewska B, Jagiello A and Jalmuzna P . (2000). Cancer Genet. Cytogenet., 121, 73–77.

  • Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA and Arnstein P . (1977). J. Natl. Cancer Inst., 58, 881–890.

  • Reznikoff CA, Kao C, Messing EM, Newton M and Swaminathan S . (1993). Semin. Cancer Biol., 4, 143–152.

  • Reznikoff CA, Loretz LJ, Christian BJ, Wu SQ and Meisner LF . (1988). Carcinogenesis, 9, 1427–1436.

  • Rigby CC and Franks LM . (1970). Br. J. Cancer, 24, 746–754.

  • Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C, Jarrard DF and Reznikoff CA . (2000). Cancer Res., 60, 3862–3871.

  • Sibley K, Cuthbert-Heavens D and Knowles MA . (2001). Oncogene, 20, 686–691.

  • Tachibana M, Miyakawa A, Tazaki H, Nakamura K, Kubo A, Hata J, Nishi T and Amano Y . (1995). Cancer Res., 55, 3438–3443.

  • Taylor CF and Taylor GR . (2004). Methods Mol. Med., 92, 9–44.

  • Theodorescu D, Cornil I, Fernandez BJ and Kerbel RS . (1990). Proc. Natl. Acad. Sci. USA, 87, 9047–9051.

  • Tzeng CC, Liu HS, Li C, Jin YT, Chen RM, Yang WH and Lin JS . (1996). Anticancer Res., 16, 1797–1804.

  • Uchida T, Wada C, Ishida H, Egawa S, Ao T, Yokoyama E and Koshiba K . (1995). Urol. Int., 55, 63–67.

  • van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH and Zwarthoff EC . (2001). Cancer Res., 61, 1265–1268.

  • van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC and Zwarthoff EC . (2004). Cancer Res., 64, 1911–1914.

  • Visvanathan KV, Pocock RD and Summerhayes IC . (1988). Oncogene Res, 3, 77–86.

  • Wagner HE, Joyce AD, Beatrice K and Summerhayes IC . (1990). Oncogene, 5, 557–563.

  • Webster MK and Donoghue DJ . (1997). Trends Genet., 13, 178–182.

  • Williams RD . (1980). Invest. Urol., 17, 359–363.

  • Williams SV, Sibley KD, Davies AM, Nishiyama H, Hornigold N, Coulter J, Kennedy WJ, Skilleter A, Habuchi T and Knowles MA . (2002). Genes Chromosomes Cancer, 34, 86–96.

  • Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM and Reznikoff CA . (1998). Genes Dev., 12, 163–174.

  • Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A and Wu XR . (2001). Oncogene, 20, 1973–1980.

  • Zhang ZT, Pak J, Shapiro E, Sun TT and Wu XR . (1999). Cancer Res., 59, 3512–3517.

Download references

Author information

Author notes

  1. Adel H Jebar and Carolyn D Hurst: These authors contributed equally to this work.

Authors and Affiliations

  1. Cancer Research UK Clinical Centre, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK

    Adel H Jebar, Carolyn D Hurst, Darren C Tomlinson, Colin Johnston & Margaret A Knowles

  2. Cancer Research UK Mutation Detection Facility, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK

    Claire F Taylor

Authors
  1. Adel H Jebar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolyn D Hurst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darren C Tomlinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Colin Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claire F Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margaret A Knowles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret A Knowles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jebar, A., Hurst, C., Tomlinson, D. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24, 5218–5225 (2005). https://doi.org/10.1038/sj.onc.1208705

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208705

Keywords

This article is cited by

Search

Advanced search

Quick links